Market Place
Sourcing Support
Enanta RSV antiviral reduces viral load in ph. 2 pediatric trial
09 Dec 2024 //
FIERCE BIOTECH
Enanta Phase 2 Zelicapavir Results for RSV in Pediatrics
06 Dec 2024 //
BUSINESSWIRE
Enanta`s RSV antiviral crushes viral load in challenge study
26 Sep 2024 //
FIERCE BIOTECH
Enanta Reports Positive EDP-323 Results In RSV Study
26 Sep 2024 //
BUSINESSWIRE
Enanta Pharmaceuticals to Participate in Investor Conferences in September
03 Sep 2024 //
BUSINESSWIRE
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter
05 Aug 2024 //
BUSINESSWIRE
Enanta At Jefferies Global Healthcare Conference
29 May 2024 //
BUSINESSWIRE
Enanta At JMP Securities Life Sciences Conference
07 May 2024 //
BUSINESSWIRE
Enanta Reports Fiscal Second Quarter Results with Webcast and Call at 4:30 p.m.
06 May 2024 //
BUSINESSWIRE
Enanta Appoints Matthew Kowalsky As Chief Legal Officer
30 Apr 2024 //
BUSINESSWIRE
Enanta Announces Inducement Grants Under Nasdaq Listing Rule
30 Apr 2024 //
BUSINESSWIRE
Enanta Pharma Q2 2024 Results Call on May 6
29 Apr 2024 //
BUSINESSWIRE
Enanta Pharma to Participate at Leerink Partners Global Biopharma Conference
06 Mar 2024 //
BUSINESSWIRE
Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter
07 Feb 2024 //
BUSINESSWIRE
Enanta Pharmaceuticals to Participate at the Oppenheimer 34th Annual Conference
06 Feb 2024 //
BUSINESSWIRE
Enanta to Provide Updates on its Research and Development Programs
04 Jan 2024 //
BUSINESSWIRE
Enanta Pharma to Present at the 42nd Annual J.P. Morgan Healthcare Conference
03 Jan 2024 //
BUSINESSWIRE
Enanta Pharmaceuticals to Participate at Evercore ISI HealthCONx Conference
22 Nov 2023 //
BUSINESSWIRE
Enanta halts work on joint hMPV-RSV drug to extend cash to 2027
21 Nov 2023 //
FIERCE BIOTECH
Enanta Pharmaceuticals to Host Conference Call
13 Nov 2023 //
BUSINESSWIRE
Enanta Pharmaceuticals to Host Virtual Key Opinion Leader Event
13 Oct 2023 //
BUSINESSWIRE
Enanta Pharma to Present Data for EDP-323 for Respiratory Syncytial Virus
17 Sep 2023 //
BUSINESSWIRE
Enanta Pharmaceuticals to Present Data for EDP-938
07 Sep 2023 //
BUSINESSWIRE
Enanta Pharmaceuticals to Participate in Investor Conferences in September
31 Aug 2023 //
BUSINESSWIRE
Enanta Reports Financial Results for its Fiscal Third Quarter with Conference
07 Aug 2023 //
PRESS RELEASE
Enanta to Host Conference to Discuss its Financial Results for Its Fiscal Q3
31 Jul 2023 //
BUSINESSWIRE
Enanta Announces Positive Data From a Phase 1 Clinical Study of EDP-323
20 Jun 2023 //
BUSINESSWIRE
Enanta Pharmaceuticals to Participate at Jefferies Global Healthcare Conference
31 May 2023 //
BUSINESSWIRE
Enanta Pharmaceuticals to Participate in Two Investor Conferences in May
09 May 2023 //
BUSINESSWIRE
Enanta makes the case for COVID-19 antiviral`s mixed data
09 May 2023 //
FIERCE BIOTECH
Enanta Reports Positive Results from Phase 2 SPRINT Trial Evaluating EDP-235
09 May 2023 //
PRESS RELEASE
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter
08 May 2023 //
BUSINESSWIRE
Enanta to Host Conference on May 8 to Discuss its Financial Results for its Q2
02 May 2023 //
PRESS RELEASE
Enanta Pharma Announces Sale of a Portion of Global Royalties on MAVYRET
25 Apr 2023 //
BUSINESSWIRE
Enanta PharmaPresents Data for its COVID-19 and Respiratory Syncytial Virus
17 Apr 2023 //
BUSINESSWIRE
Enanta Receives FDA Fast Track Designation for EDP-323
06 Apr 2023 //
BUSINESSWIRE
Enanta Pharmaceuticals to Present Data at the 33rd ECCMID
05 Apr 2023 //
BUSINESSWIRE
Enanta Pharmaceuticals to Present New Data for EDP-235
14 Mar 2023 //
BUSINESSWIRE
Enanta Pharma to Present at the Oppenheimer 33rd Annual Healthcare Conference
07 Mar 2023 //
BUSINESSWIRE
Enanta to Present at the SVB Securities Global Biopharma Conference
07 Feb 2023 //
BUSINESSWIRE
Enanta Reports Financial Results for Fiscal First Quarter Ended December 31
07 Feb 2023 //
BUSINESSWIRE
Enanta to Host Conference Call to Discuss its Financial Results for Q1
31 Jan 2023 //
BUSINESSWIRE
Enanta Pharma to Provide Updates on its R&D and 2023 Outlook
06 Jan 2023 //
BUSINESSWIRE
Enanta Pharmaceuticals to Present at the 41st Annual J.P. Morgan Conference
03 Jan 2023 //
BUSINESSWIRE
Enanta Pharmaceuticals to Participate in Two Investor Conferences in November
22 Nov 2022 //
BUSINESSWIRE
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter
21 Nov 2022 //
BUSINESSWIRE
Enanta Pharmaceuticals to Host Conference Call on November 21 at 4:30 p.m. ET
14 Nov 2022 //
BUSINESSWIRE
Enanta Initiates SPRINT, a Phase 2 Clinical Trial of EDP-235
09 Nov 2022 //
BUSINESSWIRE
Enanta Pharmaceuticals Presents New Preclinical Data for EDP-235
19 Oct 2022 //
BUSINESSWIRE
Enanta Pharmaceuticals Doses First Subject in a Phase 1 Study of EDP-323
17 Oct 2022 //
BUSINESSWIRE
Enanta commences Phase IIb trial of RSV treatment
04 Oct 2022 //
CLINICALTRIALSARENA
Enanta Initiates a Phase 2b Clinical Study of EDP-938 in High-Risk Adults
03 Oct 2022 //
BUSINESSWIRE
Enanta Pharmaceuticals Presents Preclinical Data for its RSV and hMPV Programs
29 Sep 2022 //
BUSINESSWIRE
Enanta Announces Data for Respiratory Virology Programs to be Presented
22 Sep 2022 //
BUSINESSWIRE
New Preclinical Data for EDP-235, to be Presented at IDWeek 2022
07 Sep 2022 //
BUSINESSWIRE
Enanta Pharmaceuticals to Participate in Two Investor Conferences in September
01 Sep 2022 //
BUSINESSWIRE
As Covid program advances, Enanta`s new CMO says it`s not `limited to antivirals
12 Aug 2022 //
ENDPTS
Enanta Pharma Appoints Scott T. Rottinghaus, as Senior Vice President and CMO
08 Aug 2022 //
BUSINESS WIRE
Enanta reports positive Phase I data of Covid-19 oral antiviral
01 Aug 2022 //
CLINICALTRIALSARENA
